|Slideshows|February 20, 2015

Coffee and Cancer Risk

This slide show highlights recent studies that examined coffee consumption as it relates to cancer risk, including melanoma, breast and liver cancers, and more.

References:

1. Holick CN, Smith SG, Giovannucci E, Michaud DS. Coffee, Tea, Caffeine Intake, and Risk of Adult Glioma in Three Prospective Cohort Studies. Cancer Epidemiol Biomarkers Prev. 2010;19:39-47.

2. Galeone C, Tavani A, Pelucchi C, et al. Coffee and tea intake and risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2010;19:1723-36.

3. Setiawan VW, Wilkens LR, Hernandez BY, et al. Coffee intake reduces hepatocellular carcinoma risk: The Multiethnic Cohort. American Association for Cancer Research Annual Meeting 2014; April 5–9, 2014; San Diego. Abstr LB-281.

4. Geybels MS, Neuhouser ML, Wright JL, et al. Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control. 2013;24:1947-54.

5. Sinha R, Cross AJ, Daniel CR, et al. Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study. Am J Clin Nutr. 2012;96:374-81.

6. Jiang W, Wu Y, Jiang X. Coffee and caffeine intake and breast cancer risk: an updated dose-response meta-analysis of 37 published studies. Gynecol Oncol. 2013;129:620-9.

7. Loftfield E, Freedman ND, Graubard BI, et al. Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. J Natl Cancer Inst. 2015 Jan 20. Epub ahead of print.

8. Merritt MA, Tzoulaki I, Tworoger SS, et al. Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII. Cancer Epidemiol Biomarkers Prev. 2015;24:466-71.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Latest CME

Virtual Event

North Carolina Oncology Association

2 Sessions are Available!

Coffee and Cancer Risk

References:

Related Content

43 MP2—The Next-Generation MarginProbe Device: Incremental Performance Gains in an Area of Persistent Unmet Need

44 Long-Term Oncological Outcomes After Oncoplastic Therapeutic Mammoplasty With Contralateral Symmetrisation for Early Breast Cancer: A Thirteen-Year Single-Centre Cohort Study

Overcoming PD-1 Resistance in Relapsed/Refractory Hodgkin Lymphoma

Cellular Therapy and Antibody-Drug Conjugates Shape Day 1 of ASCO Breakthrough 2026

How Should CAR-T Be Used in Diffuse Large B-Cell Lymphoma?

Latest CME

North Carolina Oncology Association

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Arkansas Association of Cancer Professionals

Rhode Island Oncology Society

Kentucky Society of Clinical Oncology

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

South Carolina Oncology Society

West Virginia Oncology Society

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Colorado Oncology Society

Montana State Oncology Society

Optimizing Treatment for Biliary Tract Cancers

Cross-Disease Integration of Immunotherapy Innovations

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

9th Annual School of Nursing Oncology™

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate